Thoracic Cancer最新文献

{"title":"Is It Safe to Omit Any Chest X-Ray Before Removing the Chest Drain After Elective, Non-Cardiac Thoracic Surgery? A Single-Center, Retrospective, Case-Control Study.","authors":"Ioannis Karampinis, Carolin Reker, Laura Grifone, Fabio Souschek, Christian Galata, Davor Stamenovic, Eric Roessner","doi":"10.1111/1759-7714.70050","DOIUrl":"10.1111/1759-7714.70050","url":null,"abstract":"<p><strong>Background: </strong>Every patient undergoing non-cardiac thoracic surgery will receive several chest X-rays through the perioperative period. The patient might receive a preoperative X-ray as a baseline as well as several X-rays before and after drain removal. This routine has several disadvantages, for the patient, the health care system and the medical staff. Purpose of this study was to examine if all X-rays before removal of the drain can be omitted.</p><p><strong>Methods: </strong>Two hundred fifty-five patients who underwent elective thoracic surgery were included in this retrospective analysis. Patients undergoing urgent procedures or empyema surgery, as well as patients with symptoms requiring further diagnostic measures or patients who required clamping of the drain before removal, were excluded.</p><p><strong>Results: </strong>Forty-five patients received an X-ray before removal of the drain, and 210 patients did not. The X-ray group developed significantly more minor complications than the no X-ray group. 46.7% of the X-rays before drain removal (X-ray group) were reported with abnormalities. However, these abnormalities never led to a change in patient care. Drainage time and postoperative hospital stay were significantly longer in the X-ray group.</p><p><strong>Conclusions: </strong>Omitting any X-ray between surgery and removal of the chest drain appears to be safe in our retrospective patient cohort. The proposed benefits of omitting the X-ray are very relevant for the health care system, the medical and nursing teams, and, more importantly, for the patients. Evidence suggests that X-ray of patients regularly do not exist. It is therefore reasonable to consider exploring this question in a formal prospective trial.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 7","pages":"e70050"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consolidation Chemotherapy Provided Survival Benefit for Esophageal Squamous Cell Carcinoma Patients Who Underwent Concurrent Chemoradiotherapy Lower Than 60 Gy.","authors":"Hualei Zhang, Qi Wang, Ping Wang, Bo Tang","doi":"10.1111/1759-7714.70012","DOIUrl":"10.1111/1759-7714.70012","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CCRT) has not been clearly defined in esophageal squamous cell carcinoma (ESCC). This study determined which patients with stage II-IVA ESCC benefitted from CCT.</p><p><strong>Methods: </strong>351 patients with ESCC were retrospectively reviewed. 185 patients received CCRT alone and 166 received CCRT plus CCT. Subset analyses were conducted on all patients' characteristics. Factors associated with survival were analyzed using the Kaplan-Meier method and a Cox proportional hazards model. The Propensity score matching (PSM) technique was used to compensate for differences in patients' characteristics.</p><p><strong>Results: </strong>The median OS were 17.7 months and 38.4 months in the CCRT alone group and CCRT+CCT group (p = 0.002), respectively. Multivariable Cox regression analysis determined that CCT was associated with improved OS (p = 0.002, HR 0.592, 95% CI 0.423-0.829); After PSM, relative to the CCRT group, patients who received CCT experienced improved OS (17.7 months vs. 38.4 months, p = 0.0139). Subgroup analysis showed that CCT was more effective in radiation dose < 60 Gy (p = 0.002, HR 0.368, 95% CI 0.194-0.700). After matching between radiation dose, in the low dose cohort, the median OS was 13.2 months and 20.7 months in the CCRT alone group and CCRT+CCT group, respectively (p = 0.0028), the multivariate analysis results showed that CCT retained its statistical significance (p = 0.002, HR 0.353, 95% CI 0.183-0.681). In the high dose cohort, the median OS were 21.6 months and 23.6 months in the CCRT alone group and CCRT+CCT group, respectively (p = 0.5512).</p><p><strong>Conclusions: </strong>We recommend that CCT treatment should be considered for ESCC patients who underwent CCRT using < 60 Gy. Further studies are needed to confirm these results.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 7","pages":"e70012"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chest Tube Drainage, Bone Radiotherapy, and Brain Radiotherapy in Advanced Lung Cancer: A Retrospective Analysis of Associated Factors and Survival.","authors":"Shoko Sonobe Shimamura, Takehito Shukuya, Kazuhisa Takahashi, Yasushi Shintani, Ikuo Sekine, Koichi Takayama, Akira Inoue, Isamu Okamoto, Tomoya Kawaguchi, Nobuyuki Yamamoto, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date","doi":"10.1111/1759-7714.70060","DOIUrl":"https://doi.org/10.1111/1759-7714.70060","url":null,"abstract":"<p><strong>Background: </strong>Palliative interventions, such as chest tube drainage and radiotherapy for bone and brain metastases, are crucial for managing survival and quality of life in patients with advanced lung cancer.</p><p><strong>Methods: </strong>This retrospective study analyzed 8171 patients with unresectable Stage IV lung cancer from the Japanese Joint Committee of Lung Cancer Registry (JJCLCR) database. At treatment initiation, 8.6% of patients underwent chest tube drainage, 9.9% underwent bone radiotherapy, and 11.5% underwent brain radiotherapy. In this study, associated factors for palliative interventions were evaluated, and their impact on patient survival was also assessed.</p><p><strong>Results: </strong>High-associated factors for upfront chest tube drainage included age ≥ 75 years, ECOG-PS ≥ 2, pleural nodules, and adenocarcinoma, while EGFR mutation, serum albumin ≥ 3.2 mg/dL, adrenal gland, and brain metastases were low-associated factors. For upfront brain radiotherapy, low-associated factors included malignant pleural effusion (MPE) and bone metastases, whereas ECOG-PS ≥ 2 was a high-associated factor. High-associated factors for upfront bone radiotherapy were serum albumin ≥ 3.2 mg/dL, ECOG-PS ≥ 2, adenocarcinoma, and squamous cell carcinoma, while pleural nodules, MPE, liver, and brain metastasis were low-associated factors. Patients receiving upfront bone radiotherapy had shorter survival, whereas survival did not significantly differ for those with or without upfront chest tube drainage or brain radiotherapy.</p><p><strong>Conclusion: </strong>This study identified associated factors for palliative interventions in advanced lung cancer and their association with overall survival. Future prospective studies with more detailed data are necessary to confirm these findings and improve clinical decision-making.</p><p><strong>Trial registration: </strong>Approval No. 15,321.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 8","pages":"e70060"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12015636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Analysis of Secondary Primary Lung Cancer After Breast Cancer Patients: Insights From a Retrospective Single-Center Study of Clinical Outcomes and Prognostic Indicators.","authors":"Miao Liu, Yao Fu, Shuai Zhu, Qian Hong, Wenjing Huang, Chen Chen, Muxan Xu, Yijia Kang, Xue Zhang, Jiagen Li","doi":"10.1111/1759-7714.70051","DOIUrl":"https://doi.org/10.1111/1759-7714.70051","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) and lung cancer are the two most common malignancies among women in China. As breast cancer diagnostic and therapeutic technologies continue to advance, the lifespan of patients with breast cancer has been extended, and the number of breast cancer patients with second primary lung cancer (SPLC) has increased. Furthermore, among women with SPLC, breast cancer stands as the most prevalent initial malignancy, and SPLC remains the predominant cause of mortality within this demographic. The aim of this retrospective study was to analyze the clinical characteristics of breast cancer with SPLC patients and to investigate postoperative survival and prognostic factors. This retrospective study analyzed 150 patients diagnosed with primary lung cancer in BC at one cancer center in China from January 2000 to December 2020.</p><p><strong>Methods: </strong>We assessed demographic data, cancer characteristics, treatment modalities, and survival outcomes. Survival curves were generated using the Kaplan-Meier method, and the significance of survival differences among selected variables was verified using the log-rank test. A univariate Cox regression analysis was used for estimating hazard ratios. A multivariate Cox regression analysis with a backward elimination method was used to estimate hazard ratios and to identify independent prognostic factors.</p><p><strong>Results: </strong>There were 29 cases (19.3%) of death. The median follow-up time for this cohort was 96.3 months. The median OS was calculated at 60.0 months, with survival rates at 1-, 3-, 5-, and 10-year marked at 89.7%, 65.5%, 44.8%, and 10.3%. The median time from BC surgical treatment to the occurrence of SPLC was observed at 4.5 months. A peak period of SPLC occurs in the first year after BC surgery. The median follow-up time from SPLC surgical treatment to death or the end of follow-up was 73.5 months. The median survival time from SPLC surgical treatment to death by any cause was 39.2 months, with survival rates at 1-, 3-, and 5-year marked at 86.2%, 51.7%, and 31.0%, and survival rates were 0% at the 9th year. The average age at BC diagnosis was 53.8 ± 10.4 years (range 25-81). 41.3% of patients had other chronic diseases. The average menarche age was 14.7 ± 1.5 years (range 11-20). 64.7% of patients had menopause. Independent prognostic factors for the BC with SPLC by multivariate analysis were the status of menopause and T-stage of SPLC.</p><p><strong>Conclusions: </strong>Further analysis revealed that patients who were menopausal and had a poor T stage of SPLC had a higher mortality rate. Based on these findings, future studies should focus on the menstrual status, hormone levels, and pathological stage of SPLC in BC patients.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 7","pages":"e70051"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.","authors":"Danyang Ji, Bo Lan, Jiayu Wang, Fei Ma, Yang Luo, Qing Li, Pin Zhang, Ruigang Cai, Qiao Li, Shanshan Chen, Binghe Xu, Ying Fan","doi":"10.1111/1759-7714.70035","DOIUrl":"10.1111/1759-7714.70035","url":null,"abstract":"<p><strong>Background: </strong>Pathological complete response (pCR) has been proven to be related to prognosis. pCR can be further classified as pCR of the breast (bpCR), pCR of axillary lymph nodes (apCR) or pCR of both tumors. The aim of this study was to elucidate the outcomes and clinicopathological characteristics associated with different patterns of pCR.</p><p><strong>Methods: </strong>Patients with node-positive disease who received neoadjuvant chemotherapy between August 2009 and July 2016 and who achieved pCR in axillary lymph nodes, breast or both were included. Multivariate logistic regression was used to identify factors related to different patterns of pCR.</p><p><strong>Results: </strong>Among the 271 patients who were included in the study, 42.1% achieved total pCR, 46.1% achieved ApCR, and 11.8% achieved BpCR. Disease-free survival (DFS) was significantly better in the total pCR group than in the limited pCR groups throughout the entire cohort (p = 0.042). Univariate and multivariate analyses indicated that patients with HR-negative disease and a high Ki-67 proliferation index were more likely to achieve total pCR. Patients with earlier T stage disease were more likely to achieve pCR only in the breast. Among patients who achieved limited pCR, there was no significant difference in terms of whether these patients received intensified adjuvant chemotherapy.</p><p><strong>Conclusions: </strong>Total pCR is still the best marker for predicting survival benefit in patients receiving neoadjuvant chemotherapy, and total pCR is more likely to be achieved in patients with HR-negative disease and a high Ki-67 proliferation index. T stage and N stage may predict apCR and bpCR, respectively.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 7","pages":"e70035"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns and Associated Outcomes in Patients With Resectable Early-Stage Non-Small Cell Lung Cancer: The THASSOS International Study.","authors":"Kumar Prabhash, Rebecca Moor, Tuncay Göksel, Jonathan Nyaw, Abdullah Khalaf Altwairgi, Francisco Gonzalez, Elsayed Mohamed, Pushpalatha Kantharaju, Farah Sadek","doi":"10.1111/1759-7714.70061","DOIUrl":"10.1111/1759-7714.70061","url":null,"abstract":"<p><strong>Background: </strong>THASSOS-INTL (NCT04808050), a multinational, retrospective study, evaluated treatment patterns and associated outcomes in patients with early-stage non-small cell lung cancer (NSCLC) from seven countries in the Asia-Pacific and the Middle-East and Africa.</p><p><strong>Methods: </strong>Eligible adult patients (≥ 18 years) with resectable clinical stage (CS) IA-IIIB NSCLC (7th AJCC) diagnosed from 01/01/2013 to 31/12/2017 were followed until death, last recorded clinical visit, or 31/12/2020 (data cut-off).</p><p><strong>Results: </strong>Of 755 patients (CS I: 30.6%, CS II: 35.0%, CS III: 34.2%) with a median age of 62 [range: 56-69] years enrolled, 69.3% were male, and 75.0% were current/ex-smokers. Of 24.2% of patients tested for EGFR, 28.4% (52/183) were positive, while 23/44 patients tested (52.3%) had PD-L1 expression (≥ 1%: 16; unknown: 7). Overall, 82.9% had surgery, of whom 39.1% (245/626) had surgery alone; 21.1% received neoadjuvant therapy, 51.1% received adjuvant therapy, and 5.8% received both; 11.2% (58/519) patients received targeted therapy (adjuvant: 47 patients; neoadjuvant: 11 patients), and 4.6% (24/519) received immunotherapy (adjuvant: 22 patients; neoadjuvant: 2 patients). The 3-year survival was 77.4% with a median overall survival (mOS) of 7.5 (95% confidence interval [CI]: 6.7-NE) years, with the highest mOS recorded with adjuvant therapy (7.5 [95% CI: 7.0-NE] years).</p><p><strong>Conclusions: </strong>This real-world study showed > 50% use of adjuvant therapy per guideline recommendations but poor use of neoadjuvant therapy. Biomarker testing at diagnosis was low, reflecting the study period being before targeted and immunotherapies. With recent approvals of newer (neo)adjuvant agents, a multidisciplinary approach is needed for better treatment decisions to improve the prognosis of early-stage NSCLC.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 8","pages":"e70061"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Recruiting Latinos for a Lung Cancer Screening Study Through a Patient Portal.","authors":"Arlette Chávez-Iñiguez, Chris De Los Reyes, Jeffrey W Ramos-Santiago, Rafael H Orfin, Victoria Uceda, Cody Gardner, Mary Jo Evans, Scott McIntosh, David H Adler, Ana Paula Cupertino, M Patricia Rivera, Francisco Cartujano-Barrera","doi":"10.1111/1759-7714.70067","DOIUrl":"https://doi.org/10.1111/1759-7714.70067","url":null,"abstract":"<p><p>The purpose of the present study was to assess the feasibility of recruiting Latinos for a lung cancer screening study through a patient portal. The electronic health record (EHR) at the University of Rochester Medical Center (URMC) was utilized to identify individuals with the following characteristics: (1) Hispanic/Latino ethnicity, (2) between 50 and 80 years old, (3) currently smoking, and (4) seen at URMC within the last 10 years. Identified individuals with an active account on MyChart (the patient portal at URMC) were messaged up to two times. The MyChart message, sent in both English and Spanish, invited individuals to participate in a study that aimed to increase the uptake of lung cancer screening among Latinos. A total of 1745 individuals in the EHR at URMC were identified as potentially eligible. Six hundred and sixty-eight individuals (38.3%, 668/1745) had an active MyChart account and were messaged. Forty-six individuals responded as interested in the study (the study interest rate was 6.8%, 46/668). Ten individuals were eligible and nine enrolled in the study (the overall enrollment rate was 1.3%, 9/668, and the enrollment/eligible rate was 90%, 9/10). It is feasible to recruit Latinos for a lung cancer screening study through a patient portal. The study interest, overall enrollment, and enrollment/eligible rates are promising and have the potential to inform future recruitment efforts because of their high-reach and low-cost.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 8","pages":"e70067"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Burden of Esophageal Cancer in Five East Asian Countries From 1990 to 2021 and Its Prediction Until 2036: An Analysis of the Global Burden of Diseases Study 2021.","authors":"Tianhao Guo, Yumo Yuan, Tingting Zhou, Yifan Hui, Yuhan Wang, Wenjian Zhu, Weixing Shen, Liu Li, Yu Yang, Haibo Cheng","doi":"10.1111/1759-7714.70045","DOIUrl":"https://doi.org/10.1111/1759-7714.70045","url":null,"abstract":"<p><strong>Background: </strong>In 2022, esophageal cancer (EC) was the eleventh most frequently diagnosed cancer and the seventh leading cause of cancer-related deaths worldwide. Nonetheless, the prevalence and burden of EC in Asian countries have been little studied. This study investigated the prevalence, incidence, and burden of EC in five East Asian countries from 1990 to 2021.</p><p><strong>Methods: </strong>We retrieved data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 on the prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) associated with EC in five East Asian countries from 1990 to 2021. The epidemiological characteristics of EC were analyzed by joinpoint regression, age-period-cohort analysis, and decomposition analysis. The burden of EC until 2036 was estimated using autoregressive integrated moving average and Bayesian age-period-cohort models.</p><p><strong>Results: </strong>Among these East Asian countries, China had the highest incidence, prevalence, mortality rates, YLLs, YLDs, and DALYs in 1990 and 2021. China and Mongolia exhibited the highest age-standardized incidence rate, age-standardized mortality rate, age-standardized prevalence rate, age-standardized YLDs rate, age-standardized YLLs rate, and age-standardized DALYs rate from 1990 to 2036. The age group with the highest prevalence rate, incidence rate, mortality rate, YLDs rate, YLLs rate, and DALYs rate in these countries was ≥ 55 years. The prevalence and incidence rates in the five countries were influenced by aging and were higher than the global average.</p><p><strong>Conclusions: </strong>The burden of EC in five East Asian countries was high over the past three decades, particularly among older adults. EC is a significant public health problem in these countries, particularly because of the large population base and aging demographics.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 8","pages":"e70045"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Advances in Bronchoscopy Through the Combination of High-Definition Bronchoscopes and New Image Processing Systems.","authors":"Kei Morikawa, Hirotaka Kida, Hiroshi Handa, Masamichi Mineshita","doi":"10.1111/1759-7714.70065","DOIUrl":"https://doi.org/10.1111/1759-7714.70065","url":null,"abstract":"<p><p>Bronchoscopy has become crucial with advances in diagnosing and treating lung cancer and interstitial pneumonia. Integrating bronchoscopes with endobronchial ultrasonography and navigation systems has significantly improved diagnostic yields and procedural safety. Although improvements in image quality and bronchoscope operability are evident, these benefits are often recognized based on widespread usage rather than objective assessment. In this study, we aimed to compare how the appearance of lesions changes depending on new modes on a case-based images, with white light observation as a standard image. High-definition bronchoscopes have introduced notable clinical advantages, enhancing direct visualization of lesions and enabling precise evaluation of histological changes. This enhanced visualization facilitates better detection of vascular patterns, which can improve safety during transbronchial biopsy by minimizing complications. The addition of the CV-1500 image processor allows for comprehensive image enhancement, such as brightening peripheral bronchi, emphasizing the structural presence of lesions and blood vessels, and estimating blood vessel depth through color tone variations reflecting absorbance differences. The combination of high-definition bronchoscopy and advanced image processing holds promise for accumulating more robust clinical knowledge and optimizing diagnostic strategies.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 7","pages":"e70065"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Non-Small-Cell Lung Cancer With Massive Malignant Ascites Treated With Chemotherapy Combined With Cell-Free and Concentrated Ascites Reinfusion Therapy.","authors":"Koichi Jingo, Haruki Hirakawa, Tomoyasu Mimori, Shinya Fujioka, Yuki Muto, Makiko Komaru, Manami Haba, Yoichiro Mitsuishi, Kazuhisa Takahashi","doi":"10.1111/1759-7714.70074","DOIUrl":"https://doi.org/10.1111/1759-7714.70074","url":null,"abstract":"<p><p>We report the case of a 65-year-old woman with stage IVB lung adenocarcinoma who developed malignant ascites during treatment. Despite multiple ascitic fluid drainages and second-line chemotherapy, the ascites progressively worsened. The initiation of cell-free and concentrated ascites reinfusion therapy (CART) led to improved abdominal distention, increased blood albumin levels, and slower ascites accumulation. To our knowledge, this is the first report of CART combined with chemotherapy for the management of malignant ascites associated with lung cancer.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 8","pages":"e70074"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12021532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}